HLA-G and melanoma: On the contrary, DNMT inhibitor 5-Aza could induce a rise in HLA-G mRNA and protein in breast cancer cells [17], which was also confirmed in renal cell carcinoma, melanoma, pancreatic cancer, ovarian cancer, glioblastoma and choriocarcinoma [18–22].